Quinazoline derivatives as VEGF inhibitors

• US 7,173,038 B1
• Filed: 11/01/2000
• Issued: 02/06/2007
• Est. Priority Date: 11/05/1999
• Status: Expired due to Term

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Astrazeneca AB (Astrazeneca PLC)
• Inventors: Hennequin, Laurent Francois Andre, Thomas, Andrew Peter, Stokes, Elaine Sophie Elizabeth
• Primary Examiner(s): Wilson; James O.
• Assistant Examiner(s): TRUONG, TAMTHOM NGO
• Application Number:
  US10/129,336
• Time in Patent Office: 2,288 Days
• Field of Search: 514/257, 514/245, 514/266.21, 514/266.22, 514/259, 544/283, 544/293
• US Class Current: 514/266.4
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links

Abstract

The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R¹ represents halogeno or C_1-3alkyl; X¹ represents —O—; R² is selected from one of the following three groups: 1) C_1-5alkylR³ (wherein R³ is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C_1-4hydroxyalkyl and C_1-4alkoxy; 2) C_2-5alkenylR³ (wherein R³ is as defined hereinbefore); 3) C_2-5alkynylR³ (wherein R³ is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as a active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of number of disease states including cancer and rheumatoid arthritis.

Claims

1. A quinazoline derivative of the formula I:

2. The quinazoline derivative as claimed in claim 1 wherein the phenyl group of formula I together with the (R¹)_m substituent:

3. The quinazoline derivative as claimed in claim 1 wherein R² is C_1-5alkylR³, wherein R³ is as defined in claim 1.

4. The quinazoline derivative as claimed in claim 1 wherein R² is piperidin-4-ylmethyl in which the piperidine ring may bear one or two substituents selected from C_1-4alkyl.

9. A quinazoline derivative as claimed in any one of claims 1–

8 in the form of a pharmaceutically acceptable salt.

10. A process for the preparation of a quinazoline derivative of formula I, as defined in claim 1, or a salt thereof which comprises:

(a) the reaction of a compound of the formula III;

11. A pharmaceutical composition which comprises as active ingredient a compound of formula I as defined in any one of claims 1–

8 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

5. A quinazoline derivative of the formula II:

6. A quinazoline derivative selected from:

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(2-fluoro-4-methylanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,

4-(2-fluoro-4-methylanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,

4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline, and

4-(4-bromo-2, 6-difluoroanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline,

or a salt thereof.

7. A quinazoline derivative selected from:

4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(4-chloro-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, and

4-(4-bromo-2,6-difluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

or a salt thereof.

8. A quinazoline derivative selected from:

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline or a salt thereof.